Abstract： Objective： To observe the clinical effect of Shugan Yunpi Decoction combined with Polyene Phosphatidylcholine in the treatment of chronic hepatitis B （CHB） with liver stagnation and spleen deficiency syndrome. Methods：A total of 106 CHB patients with liver stagnation and spleen deficiency syndrome admitted to Wenzhou TCM Hospital of Zhejiang Chinese Medical University from June 2023 to June 2024 were selected and divided into the control group and the trial group using the random number table method，with 53 cases in each group. Both groups received antiviral therapy with Entecavir. The control group was additionally treated with Polyene Phosphatidylcholine，and the trial group received additional treatment with Shugan Yunpi Decoction based on the treatment of the control group. Both groups were treated for 12 weeks. The clinical effects，virus eradication，and the liver function indicators and liver fibrosis markers before and after treatment were respectively compared between the two groups. Results： After treatment，the total effective rate was 94.34% （50/53） in the trial group，higher than that of 77.36% （41/53） in the control group （P＜0.05）. The hepatitis B virus （HBV）-DNA negativity rate was 41.51% （22/53） in the trial group， higher than that of 20.75% （11/53） in the control group （P＜0.05）. The levels of serum total bilirubin （TBil）， aspartate aminotransferase （AST），alanine aminotransferase （ALT），hyaluronidase （HA），type Ⅳ collagen （Ⅳ-C）， laminin （LN），and liver stiffness measurement （LSM） in the two groups were reduced when compared with those before treatment （P＜0.05）. The above six levels and LSM in the trial group were lower than those in the control group （P＜ 0.05）. Conclusion： Shugan Yunpi Decoction combined with Polyene Phosphatidylcholine can improve the clinical effect and virus eradication rate in CHB patients with liver stagnation and spleen deficiency syndrome，enhance the liver function，and reduce the liver fibrosis.